Prelude Therapeutics Inc
PRLDHealthcare·Biotechnology·USA·Micro·NASD·Nov 13 • 5:19 AM ET
3.48-0.04 (-1.14%)
2026-11-13 13:28 CET
Market cap
$277.69M
Revenue, TTM
22.42 USD m
Net income, TTM
-60.49 USD m
Free cash flow, TTM
-33.26 USD m
EPS diluted, TTM
-0.79
Price
PRLD against its 20, 50 and 200-day averagesPatternshover a marker to name it
49.0% under the 52-week high of 6.83 on 24 Aug 2026. 52-week low 1.30 on 3 Dec 2025. Last 15 sessions, 27.2% high to low
Volume 0.00× normal · the line is the 50-bar volume average
Setup. RS line 58
CANSLIM 4 of 6 — fails: 52-Week High/Low: 0-10% below High; Institutional Ownership: Over 50%
VCP 3 of 6 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Minervini 1 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200; 50-Day Simple Moving Average: SMA50 above SMA200; 52-Week High/Low: 0-10% below High
Zanger 0 of 5 — fails: RSI (14): Not Oversold (>50); Performance: Week +10%; 20-Day High/Low: 0-5% below High; Relative Volume: Over 1.5; 200-Day Simple Moving Average: Price above SMA200
Leaders 1 of 5 — fails: 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K; 52-Week High/Low: 0-10% below High
Breakout 0 of 4 — fails: 52-Week High/Low: New High; Relative Volume: Over 2; 50-Day Simple Moving Average: Price above SMA50; 200-Day Simple Moving Average: Price above SMA200
Growth 2 of 4 — fails: EPS Growth Next Year: High (>25%); Return on Equity: Over +15%
Quality 1 of 5 — fails: Return on Equity: Over +15%; Net Profit Margin: High (>20%); Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 25
Value 0 of 4 — fails: P/B: Under 2; Return on Equity: Over +15%; Debt/Equity: Low (<0.1) — not on the tape: P/E: Under 15
Income 0 of 4 — fails: Dividend Growth: Growing 2+ Years — not on the tape: Dividend Yield: Over 2%; Payout Ratio: Low (<20%); P/E: Under 25
Small Cap 2 of 4 — fails: Average Volume: Over 500K; 200-Day Simple Moving Average: Price above SMA200
Accumulation 3 of 4 — fails: 200-Day Simple Moving Average: Price above SMA200
Relative Strength 1 of 3 — fails: 200-Day Simple Moving Average: Price above SMA200; Average Volume: Over 500K
Profile
PRLD52-week range, 39% of the way up
1.306.83
Prelude Therapeutics, Inc. is a clinical-stage oncology company, which engages in the development of novel precision cancer medicines. It also focuses on the design and development of small molecule agents for cancer medicines. The company was founded by Krishna Vaddi in 2016 and is headquartered in Wilmington, DE.
| Index | RUT |
|---|---|
| Employees | 79 |
| IPO | Sep 25, 2020 |
| Beta | 1.20 |
| ATR, 14d | 0.31 |
| Rel volume | 0.00 |
| Short float | 9.34% |
| Insider own | 43.95% |
| Inst own | 45.80% |
Snapshot
6 groupsValuation
| Index | RUT |
|---|---|
| Market Cap | $277.69M |
| Enterprise Value | 143.58M |
| Income | -60.49M |
| Sales | 22.42M |
| Book / share | 1.68 |
| Cash / share | 1.90 |
| Dividend Est. | - |
| Dividend TTM | - |
| Dividend Ex-Date | - |
| Dividend Gr. 3/5Y | - - |
| Payout | - |
| Employees | 79 |
| IPO | Sep 25, 2020 |
Ratios
| Price / earnings | - |
|---|---|
| Forward price / earnings | - |
| Price / earnings / growth | - |
| Price / sales | 12.39 |
| Price / book | 2.08 |
| Price / cash | 1.83 |
| Price / free cash flow | - |
| Value / cash profit | - |
| Value / sales | 6.40 |
| Quick Ratio | 4.07 |
| Current Ratio | 4.07 |
| Debt / equity | 0.13 |
| Long-term debt / equity | 0.11 |
| Options and short | Yes / Yes |
Earnings
| Earnings / share | -0.79 |
|---|---|
| Earnings next year | -0.48 |
| Earnings next quarter | 0.01 |
| Earnings this year | 68.84% |
| Earnings next year | -18.41% |
| Earnings growth, 5 years | 57.36% |
| Past earnings growth | 19.05% 0.15% |
| Past sales growth | - - |
| Earnings vs last year | 55.73% |
| Sales vs last year | 220.34% |
| Earnings vs last quarter | 65.57% |
| Sales vs last quarter | - |
| Earnings | Aug 11 BMO |
| Surprise | 28.83% - |
Ownership
| Insiders own | 43.95% |
|---|---|
| Insider trades | 0.00% |
| Institutions own | 45.80% |
| Institution trades | 18.04% |
| Return on assets | -39.76% |
| Return on equity | -57.73% |
| Return on capital | -40.70% |
| Gross Margin | 92.92% |
| Operating margin | -300.56% |
| Profit Margin | -269.75% |
| 20-day average | -6.78% |
| 50-day average | -13.02% |
| 200-day average | -15.09% |
Technical
| Shares out | 65.03M |
|---|---|
| Shares floating | 44.73M |
| Short / float | 9.34% |
| Short ratio | 8.69 |
| Short interest | 4.18M |
| 52-week high | 6.83 -49.0% |
| 52-week low | 1.30 +168.7% |
| Volatility | 9.26% 8.81% |
| Average range | 0.31 |
| Strength index | 41.02 |
| Market sensitivity | 1.20 |
| Relative volume | 0.00 |
| Avg Volume | 480.74K |
| Volume | 6 |
Performance
| Perf Week | -3.34% |
|---|---|
| Perf Month | 4.81% |
| Perf Quarter | -38.19% |
| Perf Half Y | -22.33% |
| Perf YTD | 19.99% |
| Perf Year | 130.44% |
| Perf 3Y | 15.60% |
| Perf 5Y | -78.52% |
| Perf 10Y | - |
| Recommendation | 1.00 |
| Target Price | 9.20 |
| Prev Close | 3.52 |
| Price | 3.48 |
| Change % | -1.14% |
Analyst ratings
latest 10 of 20| Date | Action | Analyst | Rating change | Target | Implied |
|---|---|---|---|---|---|
| Sep 17, 2026 | Initiated | JP Morgan | Overweight | $12 | +244.9% |
| May 04, 2026 | Initiated | D. Boral Capital | Buy | $9 | +158.6% |
| Sep 19, 2024 | Upgrade | H.C. Wainwright | Neutral → Buy | $5 | +43.7% |
| Jun 20, 2024 | Downgrade | Barclays | Equal Weight → Underweight | $3 | -13.8% |
| Mar 13, 2024 | Initiated | JMP Securities | Mkt Outperform | $7 | +101.2% |
| Feb 20, 2024 | Downgrade | H.C. Wainwright | Buy → Neutral | $5 | +43.7% |
| Dec 19, 2023 | Downgrade | Morgan Stanley | Equal-Weight → Underweight | $10 → $4 | +15.0% |
| Nov 21, 2022 | Downgrade | BofA Securities | Neutral → Underperform | $8 → $6 | +72.4% |
| Sep 09, 2022 | Downgrade | Morgan Stanley | Overweight → Equal-Weight | $19 → $11 | +216.1% |
| Jul 29, 2022 | Initiated | Jefferies | Buy | $9 | +158.6% |
Peers
Mkt cap| Ticker | Company | Mkt cap |
|---|---|---|
| DMRA | Damora Therapeutics Inc | 1.36B |
| INCY | Incyte Corp | 24.81B |
| OLMA | Olema Oncology Inc | 653.52M |
| PTGX | Protagonist Therapeutics Inc | 8.77B |
| GERN | Geron Corp | 625.42M |
| ARVN | Arvinas Inc | 438.44M |
| CCCC | C4 Therapeutics Inc | 365.06M |
| KPTI | Karyopharm Therapeutics Inc | 0.39M |
| KYMR | Kymera Therapeutics Inc | 10.85B |
| PFE | Pfizer Inc | 164.73B |
Insider trading
2 filings| Insider | Relationship | Date | Transaction | Cost | Shares | Value | Total held | Form |
|---|---|---|---|---|---|---|---|---|
| Bonita David P | Director | Apr 21 '26 | Buy | 4.44 | 2,815,315 | 12,499,999 | 11,808,945 | Apr 23 06:50 PM |
| ORBIMED ADVISORS LLC | Director | Apr 21 '26 | Buy | 4.44 | 2,815,315 | 12,499,999 | 11,808,945 | Apr 23 06:48 PM |
Held by
AUM| Ticker | Company | AUM |
|---|---|---|
| VTI | Vanguard Morningstar Total Stock Market ETF | AUM: 696.31B |
| IWM | iShares Russell 2000 Index Fund | AUM: 77.86B |
| VXF | Vanguard Extended Market Index ETF | AUM: 30.79B |
| IWO | iShares Russell 2000 Growth ETF | AUM: 14.25B |
| VTWO | Vanguard Russell 2000 Index ETF | AUM: 16.90B |
| IWC | iShares Micro-Cap ETF | AUM: 1.23B |
| BUSM | EA Bridgeway Ultra-Small Company Market ETF | AUM: 112.81M |
| VTWG | Vanguard Russell 2000 Growth Index ETF | AUM: 1.43B |
| AVSC | Avantis U.S Small Cap Equity ETF | AUM: 3.33B |
| DFMC | U.S. Micro Cap Portfolio ETF Class Shares | AUM: 213.58M |
News
latest 14 of 200- Prelude Therapeutics to Participate in the Chardan Healthcare Conference (GlobeNewswire)
- Prelude Therapeutics Teams Up With Lilly To Test Experimental Breast Cancer Drug In Phase 1 Trial (Stocktwits)
- Prelude Announces Clinical Trial Collaboration and Supply Agreement with Lilly to Evaluate KAT6A Selective Degrader PRT13722 in Combination with Verzenio and Inluriyo in Patients with HR+/HER2- Breast Cancer (GlobeNewswire)
- Prelude Therapeutics to Participate in the H.C. Wainwright 28th Annual Global Investment Conference (GlobeNewswire)
- Prelude Therapeutics Receives FDA Clearance of Investigational New Drug (IND) Application for PRT13722, Its First-in-Class Oral KAT6A Selective Degrader (GlobeNewswire) -8.25%
- Sellas Experimental Drug SLS009 Appears To Be Leading The CDK9 Race, Says Alliance Global Analyst Sees About 200% Upside Potential (Stocktwits) +7.71%
- Prelude Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire) +10.14%
- Prelude Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update (GlobeNewswire)
- Prelude Therapeutics Announces Pricing of $90.0 Million Underwritten Offering (GlobeNewswire)
- Prelude Therapeutics Presents Preclinical Data from Development Candidate, PRT13722, a First-in-Class, Orally Bioavailable, Potent and Highly Selective KAT6A Degrader at American Association for Cancer Research (AACR) Annual Meeting 2026 (GlobeNewswire)
- Prelude Therapeutics Announces the Appointment of Charles Morris, M.D. as Chief Medical Officer (GlobeNewswire) +25.45%
- Prelude Therapeutics Announces Acceptance of Preclinical Abstract for PRT13722, a First-in-Class Oral KAT6A Selective Degrader at the 2026 AACR Annual Meeting (GlobeNewswire) -9.04%
- Prelude Therapeutics price target raised to $6 from $3 at Citizens (TipRanks) +5.83%
- Prelude Therapeutics Reports Full Year 2025 Financial Results and Provides Program Outlook for 2026 (GlobeNewswire) +16.50%
Quarterly earnings
2026Q2 EPS -0.140 beat -0.197, from -0.410 a year earlier. Sales 5.70 beat 0.00, from 0.00 a year earlier
The outline behind the bar is the estimate. The filled bar is the print. Green beat it, red missed it.
| Period | Reported | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | Surprise | Year-ago quarter | Analysts | Next session |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026Q2ended 2026-06-30 | 2026-08-11 08:30 | -0.140 | -0.197 | -0.140 | 5.70 | 0.00 | EPS -28.8% · sales - | vs 2025Q2, year-ago quarter · EPS -65.9% · sales - | 3 | Open +2.48% vs SPY +0.19%. Close +10.14% vs SPY -0.32% |
| 2026Q1ended 2026-03-31 | 2026-05-12 08:30 | -0.130 | -0.253 | -0.126 | 4.58 | 0.00 | EPS -48.5% · sales - | vs 2025Q1, year-ago quarter · EPS -69.0% · sales - | 4 EPS · 3 sales | Open 0.00% vs SPY -0.33%. Close -3.33% vs SPY -0.15% |
| 2025Q4ended 2025-12-31 | 2026-03-10 08:30 | -0.200 | -0.030 | -0.261 | 5.61 | 20.50 | EPS +566.7% · sales -72.6% | vs 2024Q4, year-ago quarter · EPS -45.9% · sales +40.3% | 2 | Open -3.24% vs SPY -0.08%. Close +16.50% vs SPY -0.16% |
| 2025Q3ended 2025-09-30 | 2025-11-12 08:30 | -0.260 | -0.370 | -0.259 | 6.50 | 0.00 | EPS -29.7% · sales - | vs 2024Q3, year-ago quarter · EPS -39.5% · sales +116.7% | 3 | Open +2.22% vs SPY +0.26%. Close +8.89% vs SPY +0.06% |
| 2025Q2ended 2025-06-30 | 2025-08-14 08:30 | -0.410 | -0.438 | -0.411 | 0.00 | 0.00 | EPS -6.3% · sales - | vs 2024Q2, year-ago quarter · EPS -10.9% · sales - | 4 EPS · 3 sales | Open 0.00% vs SPY -0.33%. Close +4.19% vs SPY +0.01% |
| 2025Q1ended 2025-03-31 | 2025-05-06 16:30 | -0.420 | -0.467 | -0.422 | 0.00 | 0.00 | EPS -10.0% · sales - | vs 2024Q1, year-ago quarter · EPS 0.0% · sales - | 3 EPS · 2 sales | Open +0.33% vs SPY +0.24%. Close -3.98% vs SPY +0.42% |
| 2024Q4ended 2024-12-31 | 2025-03-10 08:30 | -0.370 | -0.463 | -0.521 | 4.00 | 0.00 | EPS -20.1% · sales - | vs 2023Q4, year-ago quarter · EPS -17.8% · sales - | 3 EPS · 2 sales | Open -2.17% vs SPY -1.45%. Close -8.97% vs SPY -2.66% |
| 2024Q3ended 2024-09-30 | 2024-11-06 16:30 | -0.430 | -0.472 | -0.425 | 3.00 | 0.00 | EPS -8.9% · sales - | vs 2023Q3, year-ago quarter · EPS -4.4% · sales - | 5 EPS · 2 sales | Open 0.00% vs SPY +0.35%. Close -3.79% vs SPY +0.77% |
| 2024Q2ended 2024-06-30 | 2024-08-12 08:30 | -0.460 | -0.430 | -0.459 | 0.00 | 0.00 | EPS +7.0% · sales - | vs 2023Q2, year-ago quarter · EPS -14.8% · sales - | 4 EPS · 1 sales | Open -1.96% vs SPY +0.23%. Close -6.86% vs SPY +0.05% |
| 2024Q1ended 2024-03-31 | 2024-05-07 08:30 | -0.420 | -0.484 | -0.415 | 0.00 | 0.00 | EPS -13.2% · sales - | vs 2023Q1, year-ago quarter · EPS -27.6% · sales - | 4 EPS · 1 sales | Open +4.44% vs SPY +0.19%. Close -3.39% vs SPY +0.11% |
| 2023Q4ended 2023-12-31 | 2024-02-15 16:30 | -0.450 | -0.490 | -0.602 | 0.00 | - | EPS -8.2% · sales - | vs 2022Q4, year-ago quarter · EPS -25.0% · sales - | 3 | Open +0.57% vs SPY -0.06%. Close +33.05% vs SPY -0.50% |
| 2023Q3ended 2023-09-30 | 2023-11-01 16:30 | -0.450 | -0.583 | -0.453 | - | 0.00 | EPS -22.9% · sales - | vs 2022Q3, year-ago quarter · EPS -28.6% · sales - | 3 EPS · 1 sales | Open -6.45% vs SPY +0.93%. Close +18.82% vs SPY +1.92% |
| 2023Q2ended 2023-06-30 | 2023-08-03 08:30 | -0.540 | -0.633 | -0.541 | 0.00 | 0.00 | EPS -14.7% · sales - | vs 2022Q2, year-ago quarter · EPS -6.9% · sales - | 3 EPS · 1 sales | - |
| 2023Q1ended 2023-03-31 | 2023-05-08 08:30 | -0.580 | -0.685 | -0.581 | 0.00 | 0.00 | EPS -15.3% · sales - | vs 2022Q1, year-ago quarter · EPS -7.9% · sales - | 4 EPS · 1 sales | - |
| 2022Q4ended 2022-12-31 | 2023-03-15 08:30 | -0.600 | -0.628 | -0.598 | 0.00 | 0.00 | EPS -4.5% · sales - | vs 2021Q4, year-ago quarter · EPS -15.5% · sales - | 5 EPS · 2 sales | - |
| 2022Q3ended 2022-09-30 | 2022-11-14 08:30 | -0.630 | -0.636 | -0.631 | 0.00 | 0.00 | EPS -0.9% · sales - | vs 2021Q3, year-ago quarter · EPS -4.5% · sales - | 5 EPS · 2 sales | - |
Annual earnings
2025FY EPS -1.290 missed -1.250, from -1.680 a year earlier. Sales 12.14 missed 17.50, from 7.00 a year earlier
Reported years only. The outline behind the bar is the estimate. A later year with no print stays in the table.
earnings feed, not the snapshot. Not the statement ratio.
| Period | EPS adjusted | EPS est | EPS reported | Sales act, USD m | Sales est, USD m | P/E, earnings feed |
|---|---|---|---|---|---|---|
| 2030FYestimate | - | 0.640 | - | - | 100 | 5.44 |
| 2029FYestimate | - | 0.220 | - | - | 100 | 15.82 |
| 2028FYestimate | - | -0.100 | - | - | 100 | - |
| 2027FYestimate | - | -0.476 | - | - | 36.33 | - |
| 2026FYestimate | - | -0.402 | - | - | 43.15 | - |
| 2025FY | -1.290 | -1.250 | -1.290 | 12.14 | 17.50 | - |
| 2024FY | -1.680 | -1.773 | -1.678 | 7.00 | 1.50 | - |
| 2023FY | -2.020 | -2.040 | -2.019 | 0.00 | 0.00 | - |
| 2022FY | -2.440 | -2.474 | -2.437 | 0.00 | 0.00 | - |
| 2021FY | -2.430 | -2.413 | -2.346 | 0.00 | 0.00 | - |
| 2020FY | -4.560 | -3.695 | -1.303 | 0.00 | 0.00 | - |
Quarterly results
2026Q2 revenue 5.70, from 0.00 a year earlier. Operating margin -271.05%
From the quarterly statement. Not an estimate.
Estimate revisions
Latest snapshot of each period and type. 2026FY E -0.40 per share.
| Period | Type | Scale | Date | Mean | vs prior date |
|---|---|---|---|---|---|
| 2026FY | E | per share | 2026-10-25 | -0.40 | 0.0% |
| 2026Q3 | E | per share | 2026-10-25 | 0.01 | 0.0% |
| 2026FY | R | per share | 2026-10-25 | -0.18 | 0.0% |
| 2026Q3 | R | per share | 2026-10-25 | 0.24 | 0.0% |
| 2026FY | S | per share | 2026-10-25 | 43.15 | 0.0% |
| 2026Q3 | S | per share | 2026-10-25 | 29.00 | 0.0% |
| 2026Q2 | E | per share | 2026-07-26 | -0.20 | 0.0% |
| 2026Q2 | S | per share | 2026-07-21 | 0.00 | - |
| 2026Q2 | R | per share | 2026-05-26 | -0.22 | +7.3% |
| 2026Q1 | E | per share | 2026-05-01 | -0.25 | +1.0% |
| 2026Q1 | R | per share | 2026-05-01 | -0.23 | +18.4% |
| 2026Q1 | S | per share | 2026-04-24 | 0.00 | - |
| 2025FY | E | per share | 2026-01-26 | -1.25 | 0.0% |
| 2025Q4 | E | per share | 2026-01-26 | -0.03 | 0.0% |
| 2025FY | R | per share | 2026-01-26 | -1.23 | 0.0% |
| 2025Q4 | R | per share | 2026-01-26 | 0.12 | 0.0% |
| 2025Q4 | S | per share | 2026-01-26 | 20.50 | 0.0% |
| 2025FY | S | per share | 2026-01-17 | 17.50 | 0.0% |
| 2025Q3 | E | per share | 2025-11-06 | -0.37 | +0.7% |
| 2025Q3 | R | per share | 2025-10-28 | -0.35 | 0.0% |
| 2025Q3 | S | per share | 2025-09-22 | 0.00 | - |
| 2025Q2 | E | per share | 2025-07-21 | -0.44 | 0.0% |
| 2025Q2 | R | per share | 2025-07-21 | -0.43 | 0.0% |
| 2025Q2 | S | per share | 2025-05-07 | 0.00 | - |
| 2025Q1 | E | per share | 2025-04-07 | -0.47 | +0.4% |
| 2025Q1 | S | per share | 2025-04-07 | 0.00 | - |
| 2025Q1 | R | per share | 2025-03-10 | -0.47 | - |
| 2024FY | E | per share | 2025-03-05 | -1.77 | -0.1% |
| 2024Q4 | E | per share | 2025-03-05 | -0.46 | -0.9% |
| 2024FY | S | per share | 2025-03-05 | 1.50 | -25.0% |
| 2024FY | R | per share | 2025-01-21 | -1.77 | 0.0% |
| 2024Q4 | R | per share | 2025-01-21 | -0.47 | 0.0% |
| 2024Q4 | S | per share | 2024-11-20 | 0.00 | - |
| 2024Q3 | E | per share | 2024-10-26 | -0.47 | 0.0% |
| 2024Q3 | R | per share | 2024-10-26 | -0.48 | 0.0% |
| 2024Q3 | S | per share | 2024-08-12 | 0.00 | - |
| 2024Q2 | E | per share | 2024-08-02 | -0.43 | +2.4% |
| 2024Q2 | R | per share | 2024-08-02 | -0.43 | +9.0% |
| 2024Q2 | S | per share | 2024-05-07 | 0.00 | - |
| 2024Q1 | E | per share | 2024-05-01 | -0.48 | 0.0% |
| 2024Q1 | S | per share | 2024-03-12 | 0.00 | - |
| 2024Q1 | R | per share | 2024-02-16 | -0.46 | - |
| 2023FY | E | per share | 2024-01-20 | -2.04 | 0.0% |
| 2023FY | R | per share | 2024-01-16 | -2.03 | 0.0% |
| 2023FY | S | per share | 2023-09-26 | 0.00 | - |
Estimate history
| Metric | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM | MRQ |
|---|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.336 | -0.631 | -1.303 | -2.346 | -2.437 | -2.019 | -1.678 | -1.293 | -0.7878 | - |
| Sales USD millions | 0 | 0 | 0 | 0 | 0 | 0 | 7 | 12 | 22 | - |
| Shares million shares | 44 | 44 | 44 | 48 | 48 | 55 | 55 | 63 | - | 80 |
| Metric | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q2 '26 |
|---|---|---|---|---|---|---|---|---|---|
| EPS per share | -0.459 | -0.425 | -0.521 | -0.422 | -0.411 | -0.259 | -0.261 | -0.126 | -0.142 |
| Sales USD millions | 0 | 3 | 4 | 0 | 0 | 7 | 6 | 5 | 6 |
| Shares million shares | 55 | 55 | 55 | 56 | 57 | 57 | 63 | 63 | 80 |
Income statement, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 22.42 | 12.14+73.4% | 7.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Goods Sold Incl. D&A | 1.59 | 1.71-3.4% | 1.77+51.3% | 1.17-61.5% | 3.04+35.7% | 2.24+314.8% | 0.54+42.1% | 0.38+153.3% | 0.15 |
| Gross Profit | 20.84 | 10.43+99.4% | 5.23 | -1.17 | -3.04 | -2.24 | -0.54 | -0.38 | -0.15 |
| Selling, General and Administrative Excl. Other | 88.23 | 115.00-20.7% | 144.94+10.5% | 131.11+8.8% | 120.50+8.1% | 111.49+91.5% | 58.22+110.0% | 27.73+87.0% | 14.83 |
| Research and Development | 69.43 | 94.30-20.1% | 118.00+14.1% | 103.39+11.3% | 92.89+7.0% | 86.78+80.1% | 48.18+98.4% | 24.28+92.4% | 12.62 |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -67.40 | -104.57 | -139.71 | -132.28 | -123.54 | -113.73 | -58.76 | -28.11 | -14.97 |
| Interest Expense | - | 0.00 | - | 0.00 | 0.00 | 0.00 | 0.00 | - | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -60.49 | -99.50 | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | -14.68 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -60.49 | -99.50 | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | -14.68 |
| Net Income From Continuing Operations | -60.49 | -99.50 | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | -14.68 |
| Net Income | -60.49 | -99.50 | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | -14.68 |
| EPS (Recurring) per share | -0.61 | -1.29 | -1.68 | -2.02 | -2.44 | -2.35 | -1.30 | -0.63 | -0.34 |
| EPS (Basic, Before Extraordinaries) per share | -0.79 | -1.29 | -1.68 | -2.02 | -2.44 | -2.35 | -1.30 | -0.63 | -0.34 |
| EPS (Diluted) per share | -0.79 | -1.29 | -1.68 | -2.02 | -2.44 | -2.35 | -1.30 | -0.63 | -0.34 |
| EBITDA | -65.81 | -102.86 | -137.94 | -131.11 | -120.50 | -111.49 | -58.22 | -27.73 | -14.83 |
| Non-Operating Income (Expense) | 6.91 | 5.07-59.6% | 12.54+20.0% | 10.45+29.0% | 8.10+297.1% | 2.04+11.5% | 1.83+238.9% | 0.54+86.2% | 0.29 |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 8.29 | 11.91-44.2% | 21.34-16.7% | 25.62+1.9% | 25.14+20.1% | 20.93+275.1% | 5.58+556.5% | 0.85+372.2% | 0.18 |
| Price To Sales Ratio ratio | 23.39 | 18.38 | 13.81 | - | - | - | - | - | - |
| Gross Margin % | 92.92 | 85.91 | 74.69 | - | - | - | - | - | - |
| Operating Margin % | -300.56 | -861.33 | -1,995.91 | - | - | - | - | - | - |
| Net Margin % | -269.75 | -819.59 | -1,816.76 | - | - | - | - | - | - |
| Shares Outstanding million shares | 79.76 | 62.95+14.1% | 55.15+0.4% | 54.91+14.6% | 47.90+0.6% | 47.60+8.9% | 43.71+0.0% | 43.700.0% | 43.70 |
| Market Capitalization | 280.91 | 280.91+300.3% | 70.17-70.0% | 234.11-19.0% | 288.99-50.8% | 587.54-81.2% | 3,126.98-5.1% | 3,296.55 | - |
Income statement, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | 5.70 | 4.58 | 5.64+41.0% | 6.50+116.7% | 0.00 | 0.00 | 4.00 | 3.00 |
| Cost of Goods Sold Incl. D&A | 0.35-18.6% | 0.39-9.3% | 0.42-14.3% | 0.42+2.4% | 0.43-4.4% | 0.430.0% | 0.49+48.5% | 0.41+46.4% |
| Gross Profit | 5.35 | 4.19 | 5.22+48.7% | 6.08+133.8% | -0.43 | -0.43 | 3.51 | 2.60 |
| Selling, General and Administrative Excl. Other | 20.80-34.5% | 18.37-46.2% | 22.57-39.6% | 26.49-28.3% | 31.76-13.5% | 34.17+0.7% | 37.34+0.8% | 36.97+11.7% |
| Research and Development | 16.13-37.4% | 13.60-52.8% | 17.99-43.1% | 21.71-26.3% | 25.78-12.6% | 28.82+5.1% | 31.62+4.3% | 29.46+12.2% |
| Other Operating Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Income | -15.45 | -14.18 | -17.35 | -20.42 | -32.19 | -34.61 | -33.83 | -34.38 |
| Interest Expense | 0.00 | - | 0.00 | 0.00 | 0.00 | - | - | - |
| Unusual Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Before Taxes | -13.92 | -10.38 | -16.46 | -19.73 | -31.23 | -32.09 | -28.73 | -32.27 |
| Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Consolidated Net Income | -13.92 | -10.38 | -16.46 | -19.73 | -31.23 | -32.09 | -28.73 | -32.27 |
| Net Income From Continuing Operations | -13.92 | -10.38 | -16.46 | -19.73 | -31.23 | -32.09 | -28.73 | -32.27 |
| Net Income | -13.92 | -10.38 | -16.46 | -19.73 | -31.23 | -32.09 | -28.73 | -32.27 |
| EPS (Recurring) per share | -0.14 | -0.13 | -0.26 | -0.26 | -0.41 | -0.42 | -0.52 | -0.43 |
| EPS (Basic, Before Extraordinaries) per share | -0.14 | -0.13 | -0.26 | -0.26 | -0.41 | -0.42 | -0.52 | -0.43 |
| EPS (Diluted) per share | -0.14 | -0.13 | -0.26 | -0.26 | -0.41 | -0.42 | -0.52 | -0.43 |
| EBITDA | -15.10 | -13.79 | -16.93 | -19.99 | -31.76 | -34.17 | -33.34 | -33.97 |
| Non-Operating Income (Expense) | 1.53+59.4% | 3.79+50.4% | 0.89-82.5% | 0.69-67.1% | 0.96-60.3% | 2.52-13.4% | 5.10+18.6% | 2.10-24.5% |
| Other After Tax Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock Option Compensation Expense | 2.03-46.7% | 2.00-47.8% | 1.84-51.2% | 2.42-59.2% | 3.81-37.5% | 3.83-31.0% | 3.77-36.2% | 5.93-11.6% |
| Price To Sales Ratio ratio | 23.39 | 16.88 | 15.04 | 10.44 | 8.79 | 8.34 | 10.05 | 52.34 |
| Gross Margin % | 93.81 | 91.46 | 92.59 | 93.46 | - | - | 87.78 | 86.50 |
| Operating Margin % | -270.93 | -309.54 | -307.59 | -314.12 | - | - | -845.78 | -1,145.87 |
| Net Margin % | -244.06 | -226.75 | -291.79 | -303.46 | - | - | -718.28 | -1,075.70 |
| Shares Outstanding million shares | 79.76+40.9% | 63.02+11.6% | 62.95+14.1% | 56.60+2.9% | 56.59+2.9% | 56.45+2.8% | 55.15+0.4% | 55.03+0.4% |
| Market Capitalization | 280.91+514.7% | 215.47+312.5% | 164.18+134.0% | 81.50-28.4% | 45.70-78.2% | 52.23-83.7% | 70.17-70.0% | 113.90-32.7% |
Balance sheet, annual
| Metric | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 103.21-22.8% | 133.61-42.6% | 232.94+15.5% | 201.73-30.7% | 291.23+33.4% | 218.31+1056.3% | 18.88+21.0% | 15.60 |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 2.48+8.8% | 2.28-14.0% | 2.650.0% | 2.65-31.7% | 3.88+55.2% | 2.50+86.6% | 1.34 | 0.00 |
| Total Current Assets | 105.69-22.2% | 135.90-42.3% | 235.59+15.3% | 204.38-30.7% | 295.12+33.7% | 220.81+992.0% | 20.22+29.6% | 15.60 |
| Net Property, Plant & Equipment | 32.28-9.0% | 35.47-6.0% | 37.74+463.3% | 6.70+18.8% | 5.64+127.4% | 2.48+50.3% | 1.65+103.7% | 0.81 |
| Total Investments and Advances | 3.23-20.0% | 4.040.0% | 4.040.0% | 4.040.0% | 4.04 | 0.00 | 0.00 | 0.00 |
| Intangible Assets | - | - | - | - | - | 0.00 | 0.00 | 0.00 |
| Other Assets | 0.110.0% | 0.11-62.1% | 0.29-94.6% | 5.38+1693.3% | 0.300.0% | 0.30 | 0.00 | 0.00 |
| Total Assets | 141.31-19.5% | 175.51-36.8% | 277.67+25.9% | 220.50-27.7% | 305.10+36.5% | 223.59+922.4% | 21.87+33.3% | 16.41 |
| Short Term Debt Incl. Current Port. of LT Debt | 2.74+1.5% | 2.70+82.4% | 1.48-19.1% | 1.83+5.2% | 1.74 | 0.00-100.0% | 0.26 | 0.00 |
| Accounts Payable | 3.98 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 1.97+44.9% | 1.36 |
| Other Current Liabilities | 46.27+101.7% | 22.94+12.7% | 20.35+2.4% | 19.87+13.8% | 17.46+53.4% | 11.38+337.7% | 2.60+140.7% | 1.08 |
| Total Current Liabilities | 52.99+106.7% | 25.64+17.5% | 21.83+0.6% | 21.70+13.0% | 19.20+68.7% | 11.38+135.6% | 4.83+97.1% | 2.45 |
| Long Term Debt | 15.04-1.8% | 15.32-0.6% | 15.41 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 4.64+50.2% | 3.09-7.5% | 3.34-0.6% | 3.36 | 0.00-100.0% | 0.03+200.0% | 0.01-83.3% | 0.06 |
| Total Liabilities | 72.68+65.0% | 44.06+8.6% | 40.58+61.9% | 25.06+30.5% | 19.20+68.3% | 11.41+135.7% | 4.84+93.6% | 2.50 |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00-100.0% | 66.44+81.6% | 36.59 |
| Common Equity | 68.64-47.8% | 131.46-44.6% | 237.09+21.3% | 195.44-31.6% | 285.90+34.7% | 212.18 | -49.41 | -22.69 |
| Total Shareholders Equity | 68.64-47.8% | 131.46-44.6% | 237.09+21.3% | 195.44-31.6% | 285.90+34.7% | 212.18+1145.9% | 17.03+22.5% | 13.90 |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 68.64-47.8% | 131.46-44.6% | 237.09+21.3% | 195.44-31.6% | 285.90+34.7% | 212.18+1145.9% | 17.03+22.5% | 13.90 |
| Total Liabilities & Stockholders Equity | 141.31-19.5% | 175.51-36.8% | 277.67+25.9% | 220.50-27.7% | 305.10+36.5% | 223.59+922.4% | 21.87+33.3% | 16.41 |
| Book Value Per Share per share | 1.09-54.2% | 2.38-44.9% | 4.32+5.9% | 4.08-32.1% | 6.01+23.9% | 4.85 | -1.13 | -0.52 |
| Tangible Book Value Per Share per share | 1.09-54.2% | 2.38-44.9% | 4.32+5.9% | 4.08-32.1% | 6.01+23.9% | 4.85 | -1.13 | -0.52 |
| Full-Time Employees people | 79-39.7% | 131+2.3% | 128+4.9% | 122+5.2% | 116+70.6% | 68 | - | - |
| Price to Book Ratio ratio | 2.10 | 0.45 | 0.98 | 1.33 | 2.07 | 14.74 | 14.44 | - |
| Return on Assets % | -62.81 | -56.12 | -48.91 | -43.93 | -42.25 | -46.39 | -144.06 | - |
| Return on Equity % | -99.45 | -69.01 | -56.33 | -47.97 | -44.85 | -49.67 | -178.26 | - |
| Return on Invested Capital % | -118.90 | -86.64 | -48.25 | -59.07 | -39.07 | -26.83 | -161.88 | -105.60 |
| Quick Ratio ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 |
| Current Ratio ratio | 1.99 | 5.30 | 10.79 | 9.42 | 15.37 | 19.41 | 4.18 | 6.37 |
Cash flow, annual
| Metric | TTM | 2025FY12/31/2025 | 2024FY12/31/2024 | 2023FY12/31/2023 | 2022FY12/31/2022 | 2021FY12/31/2021 | 2020FY12/31/2020 | 2019FY12/31/2019 | 2018FY12/31/2018 |
|---|---|---|---|---|---|---|---|---|---|
| Net Income | -60.49 | -99.50 | -127.17 | -121.83 | -115.44 | -111.69 | -56.93 | -27.57 | -14.68 |
| Depreciation | 1.59 | 1.71-3.4% | 1.77+51.3% | 1.17-61.5% | 3.04+35.7% | 2.24+314.8% | 0.54+42.1% | 0.38+153.3% | 0.15 |
| Other Funds (Non Cash) | 8.90 | 13.08-28.5% | 18.30-24.0% | 24.08-13.2% | 27.73+24.3% | 22.30+298.9% | 5.59+550.0% | 0.86+330.0% | 0.20 |
| Funds from Operations | -50.00 | -84.71 | -107.10 | -96.58 | -84.66 | -87.16 | -50.79 | -26.33 | -14.34 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | 16.75 | 28.41+573.2% | 4.22 | -10.48-1226.9% | 0.93-74.3% | 3.62-21.6% | 4.62+589.6% | 0.67-51.4% | 1.38 |
| Cash from Operating Activities | -33.26 | -56.30 | -102.89 | -107.06 | -83.73 | -83.53 | -46.18 | -25.66 | -12.95 |
| Capital Expenditures | 0.00 | -0.07 | -0.76 | -3.51 | -3.02 | -2.32 | -0.62 | -0.78 | -0.53 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -77.25 | 53.53-41.1% | 90.95 | -31.13-136.7% | 84.71 | -261.48 | 0.00 | 0.00 | 0.00 |
| Purchase of Investments | -156.71 | -100.87 | -52.69 | -221.63 | -119.22 | -261.48 | 0.00 | 0.00 | 0.00 |
| Sale Or Maturity of Investments | 79.45 | 154.39+7.5% | 143.65-24.6% | 190.50-6.6% | 203.93 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -77.25 | 53.46-40.7% | 90.19 | -34.65-142.4% | 81.69 | -263.80 | -0.62 | -0.78 | -0.53 |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 110.52 | 25.04+7487.9% | 0.33-99.8% | 136.41+16740.7% | 0.81-99.5% | 164.90-33.1% | 246.49+725.8% | 29.85+66.4% | 17.94 |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 110.52 | 25.04+7487.9% | 0.33-99.8% | 136.41+16740.7% | 0.81-99.5% | 164.90-33.1% | 246.49+725.8% | 29.85+66.4% | 17.94 |
| Proceedsfrom Stock Options | 110.48 | 25.02+9166.7% | 0.27-99.8% | 136.37+31614.0% | 0.43-99.7% | 161.39-34.5% | 246.39+725.4% | 29.85+66.4% | 17.94 |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.26 | -0.12 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.26 | -0.12 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | -0.26 | -0.12 | 0.00 |
| Net Financing Active Other Cash Flow | -0.07 | -0.02 | -0.05 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Financing Activities Uses | -0.07 | -0.02 | -0.05 | -0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Financing Activities | 110.44 | 24.82 | -0.12-100.1% | 136.40+16739.5% | 0.81-99.5% | 164.90-33.0% | 246.23+728.2% | 29.73+65.7% | 17.94 |
| Net Change in Cash | -0.06 | 21.97 | -12.82 | -5.31 | -1.22 | -182.44-191.5% | 199.43+5980.2% | 3.28-26.3% | 4.45 |
| Free Cash Flow | -33.26 | -56.37 | -103.65 | -110.58 | -86.75 | -85.85 | -46.80 | -26.45 | -13.48 |
| Preferred Dividends (Cash Flow) | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Deferred Taxes & Investment Tax Credit | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Balance sheet, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & Short Term Investments | 151.76+107.3% | 81.55-17.7% | 103.21-22.8% | 54.96-64.2% | 73.22-59.3% | 99.07-50.9% | 133.61-42.6% | 153.63-33.4% |
| Short Term Receivables | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.14-14.2% | 3.04-8.7% | 2.48+8.8% | 3.37+22.1% | 3.66+27.5% | 3.33-3.2% | 2.28-14.0% | 2.76-37.4% |
| Total Current Assets | 154.90+101.5% | 84.59-17.4% | 105.69-22.2% | 58.33-62.7% | 76.88-57.9% | 102.40-50.1% | 135.90-42.3% | 156.39-33.4% |
| Net Property, Plant & Equipment | 30.79-9.1% | 31.50-9.2% | 32.28-9.0% | 33.08-9.1% | 33.89-8.7% | 34.70-7.2% | 35.47-6.0% | 36.38+413.8% |
| Total Investments and Advances | 3.40-15.8% | 3.23-20.0% | 3.23-20.0% | 3.23-20.0% | 4.040.0% | 4.040.0% | 4.040.0% | 4.040.0% |
| Other Assets | 0.27+145.5% | 0.31+181.8% | 0.110.0% | 0.11-73.2% | 0.11-73.2% | 0.11-62.1% | 0.11-62.1% | 0.41-96.7% |
| Total Assets | 189.36+64.8% | 119.64-15.3% | 141.31-19.5% | 94.75-52.0% | 114.92-48.8% | 141.26-42.8% | 175.51-36.8% | 197.22-23.7% |
| Short Term Debt Incl. Current Port. of LT Debt | 2.78+2.6% | 2.76+4.2% | 2.74+1.5% | 2.73+0.4% | 2.71-1.1% | 2.65+21.0% | 2.70+82.4% | 2.72+478.7% |
| Accounts Payable | 2.03-59.1% | 2.07-64.5% | 3.98 | 2.53-57.3% | 4.96 | 5.83 | 0.00 | 5.92 |
| Other Current Liabilities | 33.23+151.2% | 36.89+226.5% | 46.27+101.7% | 12.93-4.8% | 13.23-35.8% | 11.30-26.9% | 22.94+12.7% | 13.58-17.3% |
| Total Current Liabilities | 38.04+81.9% | 41.72+110.8% | 52.99+106.7% | 18.19-18.1% | 20.91-10.4% | 19.79+12.2% | 25.64+17.5% | 22.22+31.6% |
| Long Term Debt | 14.87-2.2% | 14.96-2.0% | 15.04-1.8% | 15.13-1.8% | 15.21-1.6% | 15.27-1.2% | 15.32-0.6% | 15.41 |
| Provision for Risks Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Liabilities | 2.72-8.4% | 2.78-8.3% | 4.64+50.2% | 2.90-7.9% | 2.97-7.5% | 3.03-7.6% | 3.09-7.5% | 3.15-6.3% |
| Total Liabilities | 55.63+42.3% | 59.46+56.1% | 72.68+65.0% | 36.22-11.2% | 39.08-7.0% | 38.08+4.7% | 44.06+8.6% | 40.79+101.4% |
| Non-Equity Reserves | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Stock - Carrying Value | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Equity | 133.73+76.3% | 60.18-41.7% | 68.64-47.8% | 58.53-62.6% | 75.84-58.4% | 103.18-51.0% | 131.46-44.6% | 156.43-34.3% |
| Total Shareholders Equity | 133.73+76.3% | 60.18-41.7% | 68.64-47.8% | 58.53-62.6% | 75.84-58.4% | 103.18-51.0% | 131.46-44.6% | 156.43-34.3% |
| Accumulated Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Equity | 133.73+76.3% | 60.18-41.7% | 68.64-47.8% | 58.53-62.6% | 75.84-58.4% | 103.18-51.0% | 131.46-44.6% | 156.43-34.3% |
| Total Liabilities & Stockholders Equity | 189.36+64.8% | 119.64-15.3% | 141.31-19.5% | 94.75-52.0% | 114.92-48.8% | 141.26-42.8% | 175.51-36.8% | 197.22-23.7% |
| Book Value Per Share per share | 1.68+25.4% | 0.96-47.5% | 1.09-54.2% | 1.03-63.7% | 1.34-59.5% | 1.83-52.3% | 2.38-44.9% | 2.84-34.7% |
| Tangible Book Value Per Share per share | 1.68+25.4% | 0.96-47.5% | 1.09-54.2% | 1.03-63.7% | 1.34-59.5% | 1.83-52.3% | 2.38-44.9% | 2.84-34.7% |
| Full-Time Employees people | - | - | 79-39.7% | - | - | - | 131+2.3% | - |
| Price to Book Ratio ratio | 2.10 | 3.14 | 2.80 | 1.07 | 0.44 | 0.32 | 0.45 | 0.62 |
| Return on Assets % | -39.76 | -59.64 | -62.81 | -76.56 | -73.30 | -65.83 | -56.12 | -57.72 |
| Return on Equity % | -57.73 | -95.25 | -99.45 | -103.99 | -96.33 | -81.44 | -69.01 | -66.64 |
| Return on Invested Capital % | -9.37 | -13.82 | -19.67 | -26.78 | -34.30 | -27.09 | -19.57 | -18.78 |
| Quick Ratio ratio | 4.07 | 2.03 | 1.99 | 3.21 | 3.68 | 5.18 | 5.30 | 7.04 |
| Current Ratio ratio | 4.07 | 2.03 | 1.99 | 3.21 | 3.68 | 5.18 | 5.30 | 7.04 |
Cash flow, quarterly
| Metric | 2026Q26/30/2026 | 2026Q13/31/2026 | 2025Q412/31/2025 | 2025Q39/30/2025 | 2025Q26/30/2025 | 2025Q13/31/2025 | 2024Q412/31/2024 | 2024Q39/30/2024 |
|---|---|---|---|---|---|---|---|---|
| Net Income | -13.92 | -10.38 | -16.46 | -19.73 | -31.23 | -32.09 | -28.73 | -32.27 |
| Depreciation | 0.35-18.6% | 0.39-9.3% | 0.42-14.3% | 0.42+2.4% | 0.43-4.4% | 0.430.0% | 0.49+48.5% | 0.41 |
| Other Funds (Non Cash) | 2.10-47.2% | 2.00-53.4% | 2.04-36.4% | 2.76-49.8% | 3.98-22.9% | 4.29-2.9% | 3.21-41.1% | 5.50-14.7% |
| Funds from Operations | -11.46 | -8.00 | -14.00 | -16.54 | -26.81 | -27.36 | -25.03 | -26.36 |
| Extraordinary Item | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Changes in Working Capital | -4.11-655.4% | -13.69 | 37.12+765.3% | -2.57 | 0.74-87.8% | -6.88 | 4.29+15.3% | -0.93 |
| Cash from Operating Activities | -15.57 | -21.68 | 23.12 | -19.11 | -26.07 | -34.23 | -20.74 | -27.30 |
| Capital Expenditures | 0.00 | 0.00 | 0.00 | 0.00 | -0.02 | -0.05 | -0.05 | -0.06 |
| Net Assets From Acquisitions | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Fixed Assets and Businesses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Purchase or Sale of Investments | -65.50-667.6% | 8.50-86.3% | -60.34-372.2% | 40.09+271.2% | 11.54-56.4% | 62.23+97.5% | 22.17+149.9% | 10.80-30.9% |
| Purchase of Investments | -89.97 | 0.00 | -66.74 | 0.00 | -24.66 | -9.46 | -7.33 | -31.99 |
| Sale Or Maturity of Investments | 24.46-32.4% | 8.50-88.1% | 6.40-78.3% | 40.09-6.3% | 36.20+5.4% | 71.70+93.8% | 29.50-56.8% | 42.79-14.0% |
| Other Uses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Sources | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash from Investing Activities | -65.50-668.6% | 8.50-86.3% | -60.34-372.8% | 40.09+273.6% | 11.52-55.9% | 62.19+99.2% | 22.12+185.8% | 10.73-28.7% |
| Cash Dividends Paid | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Preferred Dividends (Cash Flow) | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Capital Stock | 85.83+95266.7% | -0.26 | 24.95+20691.7% | 0.00-100.0% | 0.09-47.1% | 0.00 | 0.12-99.5% | 0.03-70.0% |
| Repurchase of Common Pref Stock | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Sale of Common Pref Stock | 85.83+95266.7% | -0.26 | 24.95+20691.7% | 0.00-100.0% | 0.09-47.1% | 0.00 | 0.12-99.5% | 0.03-70.0% |
| Proceedsfrom Stock Options | 85.75 | -0.29 | 25.02+6484.2% | 0.00 | 0.00 | 0.00 | 0.38-98.5% | -0.03-130.0% |
| Issuance or Reduction of Debt, Net | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Change in Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Issuance of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Reduction of Long Term Debt | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Financing Active Other Cash Flow | -0.01 | -0.05 | -0.01-104.2% | -0.01 | -0.00 | -0.01 | 0.24 | -0.16 |
| Other Financing Activities Uses | -0.01 | -0.05 | -0.01-104.2% | -0.01 | -0.00 | -0.01 | 0.24 | -0.16 |
| Cash from Financing Activities | 85.82+214450.0% | -0.31 | 24.94 | -0.01 | 0.04-33.3% | -0.16 | -0.03-100.1% | -0.13-244.4% |
| Net Change in Cash | 4.74 | -13.50-148.6% | -12.28-1016.4% | 20.97 | -14.52-565.4% | 27.80 | 1.34-85.7% | -16.69 |
| Free Cash Flow | -15.57 | -21.68 | 23.12 | -19.11 | -26.09 | -34.28 | -20.80 | -27.36 |
Revenue breakdown
USD millions, so a column adds up to the income statement. Share is of the latest year in that split. The change is versus the older year shown, not TTM.
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| Pharmaceutical Preparations | 7.00 | 12.14 | +73.4% | 100.0% |
| Total | 7.00 | 12.14 | +73.4% | 100.0% |
| Name | 2024 | 2025 | vs 2024 | 2025 share |
|---|---|---|---|---|
| United States | 7.00 | 12.14 | +73.4% | 100.0% |
| Total | 7.00 | 12.14 | +73.4% | 100.0% |
Short interest
shares short against float, oldest to newest| Settlement | Of float | Shares short | Float | Avg volume |
|---|---|---|---|---|
| 2026-10-30 | 9.34% | 4.2M | 44.7M | 490.60K |
| 2026-10-15 | 11.40% | 5.1M | 44.7M | 482.41K |
| 2026-09-30 | 10.23% | 4.6M | 44.7M | 467.03K |
| 2026-09-15 | 8.11% | 3.6M | 44.7M | 502.31K |
| 2026-08-31 | 8.03% | 3.6M | 44.7M | 480.61K |
| 2026-08-14 | 8.54% | 3.8M | 44.7M | 427.84K |
| 2026-07-31 | 8.79% | 3.7M | 41.8M | 449.89K |
| 2026-07-15 | 7.87% | 3.3M | 41.8M | 484.34K |
| 2026-06-30 | 6.76% | 2.8M | 41.8M | 480.36K |
| 2026-06-15 | 4.29% | 1.8M | 41.8M | 373.68K |
| 2026-05-29 | 3.68% | 1.7M | 46.0M | 374.38K |
| 2026-05-15 | 4.02% | 1.9M | 46.0M | 392.79K |
| 2026-04-30 | 4.69% | 1.6M | 33.2M | 348.72K |
| 2026-04-15 | 7.88% | 1.8M | 22.9M | 319.62K |
| 2026-03-31 | 10.12% | 2.3M | 22.9M | 351.13K |
| 2026-03-13 | 9.93% | 2.3M | 22.9M | 438.06K |
| 2026-02-27 | 10.93% | 2.3M | 20.8M | 441.97K |
| 2026-02-13 | 11.44% | 2.4M | 20.8M | 451.46K |
| 2026-01-30 | 9.98% | 2.1M | 20.8M | 1.52M |
| 2026-01-15 | 8.07% | 1.7M | 20.8M | 1.48M |
Option chain
expiry 2026-11-20| Type | Strike | Bid | Ask | Last | IV | Open int | Volume | Delta | Theta | Vega |
|---|---|---|---|---|---|---|---|---|---|---|
| call | 2.50 | 0.75 | 1.75 | 1.25 | 700.5% | 3.00 | 0.00 | 0.869 | -0.018 | 0.001 |
| call | 5.00 | 0.00 | 0.40 | 0.05 | 396.6% | 30.00 | 1.00 | 0.377 | -0.050 | 0.002 |
| call | 7.50 | 0.00 | 0.10 | 0.00 | 560.3% | 0.00 | 0.00 | 0.310 | -0.065 | 0.002 |
| put | 2.50 | 0.00 | 0.10 | 0.10 | 334.0% | 100 | 0.00 | -0.168 | -0.028 | 0.001 |
| put | 5.00 | 0.90 | 1.90 | 0.00 | 409.0% | 0.00 | 0.00 | -0.623 | -0.049 | 0.002 |
| put | 7.50 | 3.50 | 4.50 | 0.00 | 634.5% | 0.00 | 0.00 | -0.870 | -0.025 | 0.001 |
Latest SEC filings
30| Filed | Form | Description | Period | Link |
|---|---|---|---|---|
| 2026-09-10 | 8-K | Current report | 2026-09-10 | SEC |
| 2026-08-11 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-06-30 | SEC |
| 2026-08-11 | 8-K | Current report | 2026-08-11 | SEC |
| 2026-07-08 | SCHEDULE 13G | SEC | ||
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-10 | 4 | Statement of changes in beneficial ownership of securities | 2026-06-09 | SEC |
| 2026-06-10 | 8-K | Current report | 2026-06-09 | SEC |
| 2026-05-12 | 10-Q | Quarterly report pursuant to Section 13 or 15(d) | 2026-03-31 | SEC |
| 2026-05-12 | 8-K | Current report | 2026-05-12 | SEC |
| 2026-05-04 | 4 | Statement of changes in beneficial ownership of securities | 2026-05-01 | SEC |
| 2026-04-29 | ARS | Annual report to security holders. | 2025-12-31 | SEC |
| 2026-04-29 | DEFA14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | SEC | |
| 2026-04-29 | DEF 14A | Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 | 2026-06-09 | SEC |
| 2026-04-28 | SCHEDULE 13G | SEC | ||
| 2026-04-28 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-27 | SEC |
| 2026-04-28 | 3 | Initial statement of beneficial ownership of securities | 2026-04-21 | SEC |
| 2026-04-23 | SCHEDULE 13D/A | SEC | ||
| 2026-04-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-21 | SEC |
| 2026-04-23 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-21 | SEC |
| 2026-04-22 | 4 | Statement of changes in beneficial ownership of securities | 2026-04-21 | SEC |
| 2026-04-22 | SCHEDULE 13D/A | SEC | ||
| 2026-04-21 | 8-K | Current report | 2026-04-20 | SEC |
| 2026-04-21 | 424B5 | SEC | ||
| 2026-04-20 | 8-K | Current report | 2026-04-20 | SEC |
| 2026-04-15 | 8-K | Current report | 2026-04-15 | SEC |
| 2026-04-15 | 3 | Initial statement of beneficial ownership of securities | 2026-04-15 | SEC |
Insider activity by month
| Month | Bought | Buys | Sold | Sells |
|---|---|---|---|---|
| 2026-11 | 0 | 0 | 0 | 0 |
| 2026-10 | 0 | 0 | 0 | 0 |
| 2026-09 | 0 | 0 | 0 | 0 |
| 2026-08 | 0 | 0 | 0 | 0 |
| 2026-07 | 0 | 0 | 0 | 0 |
| 2026-06 | 0 | 0 | 0 | 0 |
| 2026-05 | 0 | 0 | 0 | 0 |
| 2026-04 | 25.00M | 2 | 0 | 0 |
| 2026-03 | 0 | 0 | 0 | 0 |
| 2026-02 | 0 | 0 | 0 | 0 |
| 2026-01 | 0 | 0 | 0 | 0 |
| 2025-12 | 0 | 0 | 0 | 0 |
| 2025-11 | 0 | 0 | 0 | 0 |
Institutional holders
| Manager | % owned |
|---|---|
| ORBIMED ADVISORS LLC | 17.23% |
| BAKER BROS. ADVISORS LP | 12.71% |
| RA CAPITAL MANAGEMENT, L.P. | 8.13% |
| Soleus Capital Management, L.P. | 4.24% |
| Kynam Capital Management, LP | 3.03% |
| VANGUARD CAPITAL MANAGEMENT LLC | 2.52% |
| BlackRock, Inc. | 2.26% |
| SPHERA FUNDS MANAGEMENT LTD. | 1.28% |
| TWO SIGMA INVESTMENTS, LP | 1.25% |
| ADAR1 Capital Management, LLC | 1.13% |
Funds
| Fund | % owned |
|---|---|
| VANGUARD TOTAL STOCK MARKET INDEX FUND | 1.90% |
| iShares Russell 2000 ETF | 0.83% |
| VANGUARD EXTENDED MARKET INDEX FUND | 0.58% |
| Fidelity Small Cap Index Fund | 0.38% |
| iShares Russell 2000 Growth ETF | 0.33% |
| Fidelity Extended Market Index Fund | 0.24% |
| SIMT Tax-Managed Small/Mid Cap Fund | 0.23% |
| VANGUARD RUSSELL 2000 INDEX FUND | 0.20% |
| iShares Micro-Cap ETF | 0.12% |
| Fidelity Total Market Index Fund | 0.09% |
OakChart. PRLD. Cached 15 minutes. Terms